PRESS RELEASE

MolMed at the World Advanced Therapies & Regenerative Medicine meeting on the strategies to enhance manufacturing of Cell & Gene therapies, and meet the increasing market demand in the field.

Milan (Italy), May 20th, 2019 - MolMed S.p.A. (MLMD.MI), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, joined the 14th edition of World Advanced Therapies & Regenerative Medicine Meeting ended on Friday in London, UK.

The World Advanced Therapies & Regenerative Medicine Meeting is one of the main international events on Cell & Gene therapies manufacturing, and hosts discussions and updates on specific issues as innovation in development and manufacturing processes, automation and scalability in the production of viral vectors and genetically modified cells for clinical trials and for the market.

Luca Alberici MolMed's Chief Business Officer took the floor on the strategies in the manufacturing of lentiviral vectors, key issue in the CAR T development, today representing one the main area of interest in the field: "*It's time to find the potential strategies to face one of the main issues of advanced therapies, and in particular of CAR Ts, represented by the high production costs. In order to meet the growing needs of the market, it is still more necessary to act on process automation and scalability, with specific regard to vectors and modified cells manufacturing, by introducing large-scale, completely single-use and closed systems, but also to favor the international standardization and automation of quality control tests. Even allogeneic CARs represent a potential opportunity to meet the need for sustainability, potentially taking a place alongside the autologous CARs, which have already demonstrated an extraordinary degree of effectiveness in some onco-hematological diseases"* commented Luca Alberici, MolMed Chief Business Officer. *"In this respect, MolMed is working on both sides: on one hand on continuous technological improvement of its own facilities, among the first in the world to obtain the authorization for GMP development and manufacturing of gene and cell therapies for the market; on the other hand, by developing a proprietary pipeline of allogeneic CARs, based on the NK (Natural Killer) innate immune system cells, obtained from healthy donors and then engineered to treat more patients, dramatically reducing costs and production times*".

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a

new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which on March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti
Investor Relations & Communication Manager
MolMed S.p.A.
+39 02 21277.205
+39 02 21277.325
investor.relations@molmed.com

Tommasina Cazzato
Press Office
Community Group
+39 345 7357751
tommasina.cazzato@communitygroup.it